These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 9663369)
1. A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia. Sasaki J; Arakawa K; Yamamoto K; Kobori S; Ageta M; Kono S Clin Ther; 1998; 20(3):539-48. PubMed ID: 9663369 [TBL] [Abstract][Full Text] [Related]
2. [A comparative long-term trial of sodium cerivastatin, a new HMG-CoA reductase inhibitor, in patients presenting with primary hypercholesterolemia]. Sasaki J; Arakawa K; Yamamoto K; Kobori S; Ageta M; Kono S Rev Med Interne; 1999 Aug; 20 Suppl 3():393s-398s. PubMed ID: 10480191 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group. Insull W; Isaacsohn J; Kwiterovich P; Ra P; Brazg R; Dujovne C; Shan M; Shugrue-Crowley E; Ripa S; Tota R J Int Med Res; 2000; 28(2):47-68. PubMed ID: 10898118 [TBL] [Abstract][Full Text] [Related]
4. Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia. Tazuma S; Yamashita G; Ochi H; Miura H; Kajihara T; Hattori Y; Miyake H; Nishioka T; Hyogo H; Sunami Y; Yasumiba S; Kajiyama G Clin Ther; 1998; 20(3):477-85. PubMed ID: 9663363 [TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of cerivastatin: phase IIa dose-ranging and dose-scheduling studies. Hunninghake DB Am J Cardiol; 1998 Aug; 82(4B):26J-31J. PubMed ID: 9737643 [TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies. Davignon J; Hanefeld M; Nakaya N; Hunninghake DB; Insull W; Ose L Am J Cardiol; 1998 Aug; 82(4B):32J-39J. PubMed ID: 9737644 [TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia. Isaacsohn J; Insull W; Stein E; Kwiterovich P; Patrick MA; Brazg R; Dujovne CA; Shan M; Shugrue-Crowley E; Ripa S; Tota R; Clin Cardiol; 2001 Sep; 24(9 Suppl):IV1-9. PubMed ID: 11594407 [TBL] [Abstract][Full Text] [Related]
8. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor. Stein EA Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538 [TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia. Stein E; Isaacsohn J; Stoltz R; Mazzu A; Liu MC; Lane C; Heller AH Am J Cardiol; 1999 May; 83(10):1433-6. PubMed ID: 10335757 [TBL] [Abstract][Full Text] [Related]
10. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia. Plosker GL; Dunn CI; Figgitt DP Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127 [TBL] [Abstract][Full Text] [Related]
11. Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety. Stein E Atherosclerosis; 1998 Sep; 139 Suppl 1():S15-22. PubMed ID: 9811154 [TBL] [Abstract][Full Text] [Related]
12. International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia. International Cerivastatin Study Group. Betteridge DJ Int J Clin Pract; 1999 Jun; 53(4):243-50. PubMed ID: 10563066 [TBL] [Abstract][Full Text] [Related]
13. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. Stein E Am J Cardiol; 1998 Aug; 82(4B):40J-46J. PubMed ID: 9737645 [TBL] [Abstract][Full Text] [Related]
14. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Simons LA Am J Cardiol; 2002 Oct; 90(7):737-40. PubMed ID: 12356387 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. Hunninghake D; Insull W; Knopp R; Davidson M; Lohrbauer L; Jones P; Kafonek S Am J Cardiol; 2001 Sep; 88(6):635-9. PubMed ID: 11564386 [TBL] [Abstract][Full Text] [Related]
17. Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia. Stein E; Sprecher D; Allenby KS; Tosiello RL; Whalen E; Ripa SR J Cardiovasc Pharmacol Ther; 1997 Jan; 2(1):7-16. PubMed ID: 10684437 [TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind comparison of cerivastatin and lovastatin for treatment of primary hypercholesterolemia. Yu WC; Chen CH; Tsao HM; Ding YA Zhonghua Yi Xue Za Zhi (Taipei); 2002 Jun; 65(6):260-7. PubMed ID: 12201566 [TBL] [Abstract][Full Text] [Related]
19. A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women. Ozsener S; Sendag F; Koc T; Terek MC; Oztekin K; Bilgin O J Obstet Gynaecol Res; 2001 Dec; 27(6):353-8. PubMed ID: 11794823 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus. Scharnagl H; Winkler K; Mantz S; Baumstark MW; Wieland H; März W Exp Clin Endocrinol Diabetes; 2004 May; 112(5):269-77. PubMed ID: 15146374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]